CML and Tyrosine Kinase Inhibitors Case

Author: Dr. Aneesh Thakore, Dr. Danyal Ladha, University of Toronto

Reviewer: Dr. Hassan Sibai, Assistant Professor of Medicine, Faculty of Medicine, University of Toronto and Staff Physician, Division of Medical Hematology & Oncology, Princess Margaret Cancer Centre

Learning Objectives:

As the end of this self-assessment module, participants should be able to:

• Describe the mechanism of action of therapies used in chronic myeloid leukemia (CML)
• Describe the different prognostic scores used in CML and how they are used to guide treatment decisions
• Describe the mechanism of action, adverse effects, and benefits of bosutinib when used in the treatment of CML

Scientific Planning Committee

Dr. Danyal Ladha – Resident Physician, Hematology
Dr. Joanne Britto – Clinical Fellow, Malignant Hematology (Lymphoproliferative Disorders)
Dr. Yan Xu – Fellow Physician, Hematology/Thrombosis
Dr. Siraj Mithoowani – Clinical Hematologist at St. Joseph’s Healthcare, Hamilton
Dr. Hassan Sibai – Assistant Professor of Medicine, Faculty of Medicine, University of Toronto and Staff Physician,
Division of Medical Hematology & Oncology, Princess Margaret Cancer Centre

Conflict of Interest: None